Southwest Synthetic Pharmaceutical

The core subsidiary of Southwest Synthetic Pharmaceutical Group -- PKU International Hospital Group Southwest Synthetic Pharmaceutical Co., Ltd., is a pilot enterprise for innovation in China, a key backbone enterprise in the national pharmaceutical industry, the largest production, research and export base for biological and chemically synthesized drugs in western China, the largest sulfonamide drug production base in the world and the largest lovastatin production base in the world, a key high-tech enterprise of the National Torch Program, and a key export best-selling brand enterprise supported by Chongqing Municipality.

Southwest Synthetic has a technology center, with more than 10 major categories and over one hundred APIs and finished dosage forms. New product R&D and exports are mainly oriented to high-end markets such as Europe and the United States. All products have passed GMP certification, among which 12 products have passed U.S. FDA certification and 6 products have obtained European COS certificates, making it the Chinese pharmaceutical enterprise with the most international certifications at present. In 2009, Southwest Synthetic successfully implemented a targeted additional issuance, and the high-quality assets of Chongqing Daxin Pharmaceutical were injected into Southwest Synthetic, achieving expansion through alliance and becoming the largest manufacturing base in Chongqing for supplying pharmaceutical products to the international market.